New Medical Director to Oversee NSCLC Trial

Belgian-French clinical stage biotech PDC*line Pharma, developers of a new class of potent and scalable active immunotherapies for cancer has appointed Dr Channa Debruyne as Medical Director to lead its clinical research team. A Belgian board-certified medical doctor and specialist in pharmaceutical medicine, Dr DeBruyne will be responsible for the  management of its ongoing trial in non-small-cell lung cancer (NSCLC).

The objectives of the phase I/II study (PDC-LUNG-101) are to assess safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate, PDC*lung01, associated or not with anti-PD-1 treatment in NSCLC. A total of 66 evaluable HLA-A*02:01 positive NSCLC patients will be included in the study at three clinical centers in Belgium and six sites in France. The company obtained authorizations to start the trial in both countries in Q2, 2019.

“We are very pleased to welcome Dr Channa Debruyne, who will play a key role in the development of PDC*line Pharma’s clinical plan. She has the experience and expertise we are looking for to strengthen our management team,” said Eric Halioua, president & CEO at PDC*line Pharma. “With more than 25 years international experience in clinical and scientific research in chemotherapeutic products and cancer vaccines, she will lead the ongoing phase I/II trial with our cancer vaccine.

Dr Channa Debruyne said: “It is with great pleasure that I join PDC*line Pharma. I look forward to working in close collaboration with the PDC*line Pharma management team to bring this cancer vaccine with a breakthrough technology to patients.